folder

Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis

Authors

  • C.M. Arends
  • J. Galan-Sousa
  • K. Hoyer
  • W. Chan
  • M. Jäger
  • K. Yoshida
  • R. Seemann
  • D. Noerenberg
  • N. Waldhueter
  • H. Fleischer-Notter
  • F. Christen
  • C.A. Schmitt
  • B. Dörken
  • U. Pelzer
  • M. Sinn
  • T. Zemojtel
  • S. Ogawa
  • S. Märdian
  • A. Schreiber
  • A. Kunitz
  • U. Krüger
  • L. Bullinger
  • E. Mylonas
  • M. Frick
  • F. Damm

Journal

  • Leukemia

Citation

  • Leukemia 32 (9): 1908-1919

Abstract

  • Clonal hematopoiesis of indeterminate potential (CHIP) occurs in an age-related manner and associates with an increased risk of hematologic cancer, atherosclerotic disease, and shorter overall survival. Little is known about the cell of origin, repartition patterns of clonal mutations within the hematopoietic differentiation tree, and its dynamics under evolutionary pressure. Using targeted sequencing, CHIP was identified in 121 out of 437 elderly individuals (27.7%). Variant allele frequencies (VAFs) of 91 mutations were studied in six peripheral blood cell fractions. VAFs were significantly higher in monocytes, granulocytes, and NK-cells compared to B- or T cells. In all cases with available bone marrow material, mutations could be identified in LinCD34CD38HSCs with subsequent expansion to myeloid primed progenitors. In 22 patients with solid cancer receiving (radio-)chemotherapy, longitudinal study of 32 mutations at 121 time points identified relative VAF changes of at least 50% in 13/32 mutations. VAFs of DNMT3A, were stable in 12/13 cases (P < .001). Cancer patients with a clonal mutation other than DNMT3A required more often red blood cell transfusions and dose reductions. Our results provide novel insights into cellular distribution of clonal mutations, their dynamics under chemotherapy, and advocate for systematic analyses for CHIP in cancer patients.


DOI

doi:10.1038/s41375-018-0047-7